Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a division of Japan Clinical Oncology Group (JCOG)

Japanese Journal of Clinical Oncology

Volumn 41, Issue 12, 2011, Pages 1315-1321

  Boku, Narikazu ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Gastric cancer; Gastrointestinal Oncology Study Group; Japan Clinical Oncology Group; Pancreatic cancer, colorectal cancer

Indexed keywords

CISPLATIN; DOXIFLURIDINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NEDAPLATIN; PACLITAXEL; TEGAFUR; URACIL;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE SEVERITY; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; JAPAN; METASTASIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; JAPAN; MULTICENTER STUDIES AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 82955240729     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr129     Document Type: Article

References (30)

1. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S. A cooperative randomized study on tegafur plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991;82:613-20.
2. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, et al. A phase II study of combination therapy with 50-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993;72:658-62.
3. Shimada Y, Yoshida S, Ohtsu A, Seki S, Saito H. A phase II study of EAP (etoposide, adriamycin and cisplatin) in the patients with advanced gastric cancer multi-institutional study. J Jpn Soc Cancer Ther 1991;26: abstract #280 (in Japanese).
4. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994;30A:2091-93.
5. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-5.
6. Yamamichi N, Shirao K, Hyodo I, Koizumi W, Koizumi W, Seki S, et al. Phase II study of sequential methotrexate and 5-fluorouracil for unresectable gastric cancer. J Jpn Soc Cancer Ther 1995;30: abstract #1317 (in Japanese).
7. Ikeda N, Shimada Y, Ohtsu A, Boku N, Tsuji Y, Saito H, et al. A phase II study of doxifluridine in elderly patients with advanced gastric cancer: Japan Clinical Oncology Group Study (JCOG9410). Jpn J Clin Oncol 2002;32:90-4.
8. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al. A phase II study of sequential methotrexate and 5-fluorouracil for advanced gastric cancer with malignant ascites: a report from the gastrointestinal oncology study group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004;34:316-22.
9. Ohtsu A, Boku N, Yoshioka T, Hyodo I, Shirao K, Shimada Y, et al. A phase II study of Irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group (JCOG9703). Jpn J Clin Oncol 2003;33:28-32.
10. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG Trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2010 Oct 5 [Epub ahead of print].
11. Ishikura S, Ohtsu A, Shirao K, Muro K, Kagami Y, Nihei K, et al. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG9908). Esophagus 2005;2:133-7.
12. Yamada Y, Shirao K, Hyodo I, Arai Y, Denda T, Ambo T, et al. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer Chemother Pharmacol 2003;52:125-30.
13. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: randomised phase 3 study. Lancet Oncol 2009;10:1063-9.
14. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, et al. Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). Annual Meeting of ASCO 2009; abstract #4545.
15. Hamaguchi T, Shirao K, Ohtsu A, Hyodo I, Arai Y, Takiuchi H, et al. A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer 2011;14:226-33.
16. Takiuchi H, Fukuda H, Boku N, Shimada Y, Nasu J, Hamamoto Y, et al. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). Annual Meeting of ASCO 2010; abstract #4052.
17. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 2010;40:573-9.
18. Kurokawa Y, Muto M, Minashi K, Boku N, Fukuda H; for the Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group (JCOG). A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508. Jpn J Clin Oncol 2009;39:686-9.
19. Kurokawa Y, Hasuike N, Ono H, Boku N, Fukuda H, for the Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group (JCOG). A phase II trial of endoscopic submucosal dissection for mucosal gastric cancer Japan Clinical Oncology Group Study JCOG0607. Jpn J Clin Oncol 2009;39:464-6.
20. Nakamura K, Tahara M, Kiyota N, Hayashi R, Akimoto T, Fukuda H, et al. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706). Jpn J Clin Oncol 2009;39:460-3.
21. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4:1469-74.
22. Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hyodo I, et al. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007;37:275-81.
23. Yamada Y, Yamamoto S, Ohtsu A, Suzuki Y, Nasu J, Yamaguchi K, et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. Annual Meeting of ASCO 2009; abstract #4535.
24. Yamada Y, Mizusawa J, Takashima A, Nakamura K, Tsuji Y, Suzuki Y, et al. Molecular prognostic markers in advanced gastric cancer Correlative study in the Japan clinical oncology group trial JCOG9912. Annual Meeting of ASCO 2011; abstract #3021.
25. Cullinan SA, Moertel CG, Fleming TR, Krook JE, Everson LK, Windschitl HE, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7.
26. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, et al. A phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
27. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
28. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
29. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
30. Takashima A, Boku N, Kato K, Mizusawa J, Nakamura K, Fukuda H, et al. Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC)-results from combined analysis of JCOG9205 and JCOG9912. Annual Meeting of ASCO 2010; abstract #4061.